changing hearts, minds, and the addiction treatment industry
Our Boulder Vision
Our Recovery Community
Policy & Advocacy
Research & Education
Articles tagged:
buprenorphine
Policy & Advocacy
A "Wobble" is not a Win:
The New York Times this week reported a ~3% annual decline in national overdose deaths, and asked, “Has fentanyl peaked?” It hasn’t — and we’ve made this mistaken assumption before, with irrevocable consequences. Here’s what we know:
Stephanie Strong
CEO & Founder
Policy & Advocacy
A plea from the frontlines:
Telehealth treatment for opioid addiction is working. Pandemic flexibilities helped Americans access life-saving medications like buprenorphine without increasing misuse. So why are we going backward? The DEA’s newly proposed “guardrails” are more aptly “roadblocks” for addiction patients and providers alike.
Susanne Johnson MSN, FNP-BC
Nurse Practitioner
Policy & Advocacy
What the DEA's Proposed Changes to Telemedicine Really Mean
The DEA announced a proposal for new rules for prescribing controlled substances - including buprenorphine - that could impact telehealth patients and add a single in-person requirement. Boulder is prepared to help patients navigate this change and fight back to make treatment easy and accessible.
Stephanie Strong
CEO & Founder
Policy & Advocacy
The Ways We Regulate Stigma into Law
Ben MacLean, Boulder's General Counsel, explains how laws and regulations can fight against patients with SUDs and stand in the way of better treatment options.
Ben Maclean
General Counsel
Our Boulder Vision
The Rewarding Truth of Prescribing Suboxone
Alyson Smith, Boulder Care’s Medical Director, shares how rewarding working with SUD patients has been for her and how urgent the need is for more clinicians to do the same.
Alyson Smith, MD
Former Medical Director